Admin

Press Release

Hepion Pharmaceuticals Receives Positive FDA Response on GV104 in Gambling Disorder, a Condition With No Approved Medication

- FDA's Division of Psychiatry issued written responses to a Type B pre-IND meeting request covering the regulatory pathway, the nonclinical package, and the design of a planned Phase 2…

AdminOctober 19, 2026

Press Release

Hepion Pharmaceuticals Completes Acquisition of Gravitas Life Sciences and Provides Corporate Update

- Acquisition adds GV104, a clinical-stage opioid countermeasure with a 505(b)(2) pathway and an active investigational new drug application, and GV023, an oral formulation of an approved anti-TNF antibody --…

AdminOctober 14, 2026

NASH on the Cusp: An Emerging Market Opportunity [BioSpace]

https://www.biospace.com/article/nash-on-the-cusp-an-emerging-market-opportunity-/

Media Placements Videos

Edmonton-based Hepion Developing Novel Liver Drug [Global News]

AdminJune 23, 2023

As it awaits key readout, Hepion boosts confidence in NASH drug hopeful via shorter study [Endpoints]

https://endpts.com/as-it-awaits-key-readout-hepion-boosts-confidence-in-nash-drug-hopeful-via-shorter-study/

Fatty Liver, NASH, Cirrohosis – Can They Be Stopped??? [BioTech Nation]

https://www.biotechnation.com/episodes/fatty-liver-nash-cirrohosis-can-they-be-stopped

Media Placements Videos

Hepion Pharmaceuticals 2023 NASDAQ Closing Bell

AdminFebruary 20, 2023

GEN2 NASH Therapies Near the Finish Line [Biospace]

https://www.biospace.com/article/gen2-nash-therapies-near-the-finish-line-/

What I Learned As CEO The First Time Around [Life Science Leader]

https://www.lifescienceleader.com/doc/what-i-learned-as-ceo-the-first-time-around-0001

Hepion Pharmaceuticals’ Lead Therapy, Rencofilstat [Oncology Tube]

https://oncologytube.com/v/41256#gsc.tab=0